BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 30967867)

  • 1. Mycobacterial Evolution Intersects With Host Tolerance.
    Saelens JW; Viswanathan G; Tobin DM
    Front Immunol; 2019; 10():528. PubMed ID: 30967867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?
    Park HE; Lee W; Shin MK; Shin SJ
    Front Immunol; 2021; 12():703060. PubMed ID: 34262571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The arms race between man and Mycobacterium tuberculosis: Time to regroup.
    Hoal EG; Dippenaar A; Kinnear C; van Helden PD; Möller M
    Infect Genet Evol; 2018 Dec; 66():361-375. PubMed ID: 28843547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural and trained innate immunity against Mycobacterium tuberculosis.
    Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
    Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting immunometabolism in host defence against Mycobacterium tuberculosis.
    Sheedy FJ; Divangahi M
    Immunology; 2021 Feb; 162(2):145-159. PubMed ID: 33020911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for Highly Variable, Region-Specific Patterns of T-Cell Epitope Mutations Accumulating in
    Ramaiah A; Nayak S; Rakshit S; Manson AL; Abeel T; Shanmugam S; Sahoo PN; John AJUK; Sundaramurthi JC; Narayanan S; D'Souza G; von Hoegen P; Ottenhoff THM; Swaminathan S; Earl AM; Vyakarnam A
    Front Immunol; 2019; 10():195. PubMed ID: 30814998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.
    Abreu R; Giri P; Quinn F
    Front Immunol; 2020; 11():1553. PubMed ID: 32849525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-evolution of Mycobacterium tuberculosis and Homo sapiens.
    Brites D; Gagneux S
    Immunol Rev; 2015 Mar; 264(1):6-24. PubMed ID: 25703549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerating the Unwelcome Guest; How the Host Withstands Persistent
    Olive AJ; Sassetti CM
    Front Immunol; 2018; 9():2094. PubMed ID: 30258448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobacterial Genetic Technologies for Probing the Host-Pathogen Microenvironment.
    Adefisayo OO; Curtis ER; Smith CM
    Infect Immun; 2023 Jun; 91(6):e0043022. PubMed ID: 37249448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensing of Mycobacterium tuberculosis and consequences to both host and bacillus.
    Stamm CE; Collins AC; Shiloh MU
    Immunol Rev; 2015 Mar; 264(1):204-19. PubMed ID: 25703561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular vesicles in the context of Mycobacterium tuberculosis infection.
    Palacios A; Gupta S; Rodriguez GM; Prados-Rosales R
    Mol Immunol; 2021 May; 133():175-181. PubMed ID: 33743266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of virulence in the Mycobacterium tuberculosis complex.
    Orgeur M; Brosch R
    Curr Opin Microbiol; 2018 Feb; 41():68-75. PubMed ID: 29216510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into the evasion of host innate immunity by Mycobacterium tuberculosis.
    Chai Q; Wang L; Liu CH; Ge B
    Cell Mol Immunol; 2020 Sep; 17(9):901-913. PubMed ID: 32728204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissecting Host-Pathogen Interactions in TB Using Systems-Based Omic Approaches.
    Borah K; Xu Y; McFadden J
    Front Immunol; 2021; 12():762315. PubMed ID: 34795672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling the potential impact of host population survival on the evolution of M. tuberculosis latency.
    Zheng N; Whalen CC; Handel A
    PLoS One; 2014; 9(8):e105721. PubMed ID: 25157958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for Tuberculosis.
    Guler R; Ozturk M; Sabeel S; Motaung B; Parihar SP; Thienemann F; Brombacher F
    Front Immunol; 2021; 12():733853. PubMed ID: 34745105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond Killing
    Divangahi M; Khan N; Kaufmann E
    Front Immunol; 2018; 9():2976. PubMed ID: 30619333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.